Back to discover
Disease

Trypanosomiasis, African

Late-stage therapeutic developmentEmerging research
MeSHTrypanosomiasis, African
1
Publications
8
Clinical trials
2023
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Anti-trypanosomatid drug discovery: progress and challenges.

Research2022-08-22Nature reviews. Microbiology

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial with recent milestones (1 completed or reporting results).
Clinical Milestones1View
Recently completed 1
Activity timeline1

Clinical trials

3 sponsors · 0 new · 1 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
8
All trials
0
Active
5
Late-stage
5
Completed
Late-stage studies

Pharmacokinetic, Efficacy, Safety, and Tolerability Study of a Single Dose of Acoziborole Under Fasting Conditions in Paediatric Patients From 1 to 14 Years of Age and With g-HAT: a Multicentre, Open-label Study

Phase 2/3 · Completed · Drugs for Neglected Diseases

Efficacy and Safety of Fexinidazole in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Rhodesiense: a Multicentre, Open-label Clinical Trial

Phase 2/3 · Completed · Drugs for Neglected Diseases

Clinical Study Comparing the Nifurtimox-Eflornithine Combination With the Standard Eflornithine Regimen for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis in the Meningoencephalitic Phase

Phase 3 · Completed · Drugs for Neglected Diseases

Clinical Trial Comparing the Therapeutic Combinations Melarsoprol-Nifurtimox, Melarsoprol-Eflornithine and Eflornithine-Nifurtimox in the Treatment of Gambiense Human African Trypanosomiasis in the Meningo-Encephalitic Phase

Phase 3 · Terminated · Epicentre

Efficacy and Safety of an Eflornithine + Nifurtimox Combination for Treatment of Late-Stage Human African Trypanosomiasis (HAT) in West Nile, Uganda

Phase 2/3 · Terminated · Epicentre
Recently completed

Pharmacokinetic, Efficacy, Safety, and Tolerability Study of a Single Dose of Acoziborole Under Fasting Conditions in Paediatric Patients From 1 to 14 Years of Age and With g-HAT: a Multicentre, Open-label Study

Phase 2/3 · Completed · Drugs for Neglected Diseases

Efficacy and Safety of Fexinidazole in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Rhodesiense: a Multicentre, Open-label Clinical Trial

Phase 2/3 · Completed · Drugs for Neglected Diseases

Randomized, Double-blind, Placebo-controlled Sequential Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SCYX-7158 After Single Oral Ascending Doses in Healthy Male Volunteers

Phase 1 · Completed · Drugs for Neglected Diseases

Clinical Study Comparing the Nifurtimox-Eflornithine Combination With the Standard Eflornithine Regimen for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis in the Meningoencephalitic Phase

Phase 3 · Completed · Drugs for Neglected Diseases

Phase II A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis

Phase 2 · Completed · Immtech Pharmaceuticals, Inc

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

Anti-trypanosomatid drug discovery: progress and challenges.

Nature reviews. Microbiology · 2023 · 122 cites
Recent publications

Anti-trypanosomatid drug discovery: progress and challenges.

Nature reviews. Microbiology · 2023 · 122 cites
Major themes3
  • Chagas Disease1
  • Leishmaniasis1
  • Trypanosomiasis, African1
Leading journals1
  • Nature reviews. Microbiology1
Leading researchers5
  • De Rycker M1
  • Gilbert IH1
  • Horn D1
  • Read KD1
  • Wyllie S1
Affiliations (unnormalised)1
  • Wellcome Centre for Anti-Infectives Research1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A disease endemic among people and animals in Central Africa. It is caused by various species of trypanosomes, particularly T. gambiense and T. rhodesiense. Its second host is the TSETSE FLY. Involvement of the central nervous system produces African sleeping sickness. Nagana is a rapidly fatal trypanosomiasis of horses and other animals.

Identifiers
MeSHTrypanosomiasis, African
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.